FY2029 Earnings Forecast for Geron Issued By HC Wainwright

Geron Co. (NASDAQ:GERN) – Investment analysts at HC Wainwright issued their FY2029 EPS estimates for Geron in a report released on Wednesday, February 26th. HC Wainwright analyst E. Bodnar expects that the biopharmaceutical company will earn $0.60 per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Geron (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). The business had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%.

Several other research firms have also commented on GERN. Needham & Company LLC reduced their price target on Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday. Scotiabank decreased their price target on Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a report on Thursday. Stifel Nicolaus cut their target price on Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday. B. Riley lowered shares of Geron from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $3.50 to $2.00 in a research note on Thursday. Finally, Barclays restated an “overweight” rating and set a $4.00 target price (down from $9.00) on shares of Geron in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Stock Up 1.1 %

GERN opened at $1.76 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of -5.50 and a beta of 0.53. Geron has a fifty-two week low of $1.46 and a fifty-two week high of $5.34. The company has a fifty day moving average of $2.93 and a two-hundred day moving average of $3.77.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in GERN. SBI Securities Co. Ltd. acquired a new stake in shares of Geron in the 4th quarter valued at approximately $28,000. Integrated Wealth Concepts LLC acquired a new stake in Geron during the fourth quarter worth approximately $36,000. GF Fund Management CO. LTD. acquired a new stake in Geron during the fourth quarter worth approximately $45,000. Fifth Lane Capital LP acquired a new position in shares of Geron during the 4th quarter worth approximately $53,000. Finally, Readystate Asset Management LP acquired a new position in shares of Geron during the 3rd quarter worth approximately $58,000. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.